TDP-43 pathology is a key pathological finding in corticobasal syndrome (CBS), present in approximately 40-50% of cases. This proteinopathy, characterized by cytoplasmic inclusions of the TDP-43 protein, represents a major pathological substrate underlying CBS and has significant implications for diagnosis, prognosis, and therapeutic development.
¶ Prevalence and Classification
CBS demonstrates remarkable pathological heterogeneity. Based on autopsy studies:
| Pathological Subtype |
Prevalence |
Key Features |
| Tau-predominant (4R tau) |
50-55% |
CBD-type tau pathology, astrocytic plaques |
| TDP-43 predominant |
25-35% |
Motor neuron disease-type inclusions |
| Alzheimer's disease comorbidity |
15-20% |
Aβ plaques, tau NFTs |
| α-Synuclein comorbidity |
5-10% |
Lewy bodies |
| Mixed pathology |
10-15% |
Multiple proteinopathies |
The TDP-43 predominant subgroup represents a distinct pathological entity:
- Neuronal cytoplasmic inclusions: Ubiquitin-positive, TDP-43 positive
- Neuronal intranuclear inclusions: Less common but specific
- ** dystrophic neurites**: In affected regions
- Limited tau pathology: May show minimal 4R tau involvement
TDP-43 pathology in CBS shows characteristic patterns:
-
Motor Cortex (BA4, BA6)
- Highest burden
- Correlates with cortical signs (apraxia, alien limb)
-
Premotor and Supplementary Motor Areas
- Significant involvement
- Associated with motor planning deficits
-
Posterior Parietal Cortex
- Variable involvement
- Correlates with spatial processing deficits
-
Basal Ganglia
- Moderate involvement
- Contributes to movement disorders
-
Brainstem and Spinal Cord
- Variable involvement
- May show involvement of corticospinal tracts
flowchart TD
A["TDP-43 Protein<br/>Nuclear Dysfunction"] --> B["Cytoplasmic Mislocalization"]
B --> C["Aggregation"]
C --> D["Inclusion Formation"]
D --> E["Neuronal Cytoplasmic<br/>Inclusions NCI"]
D --> F["Neuronal Intranuclear<br/>Inclusions NII"]
D --> G["Dystrophic<br/>Neurites DN"]
E --> H["Cell Dysfunction"]
F --> H
G --> H
H --> I["Synaptic Loss"]
H --> J["Axonal Degeneration"]
H --> K["Neuronal Death"]
style A fill:#e1f5fe
style D fill:#ffcdd2
style H fill:#ffebee
| Disease |
TDP-43 Burden |
Regional Pattern |
Inclusions Type |
| CBS |
Moderate-high |
Frontoparietal > motor |
NCI > NII |
| ALS |
High |
Motor cortex, spinal cord |
NCI dominant |
| FTLD-TDP |
High |
Frontal, temporal |
NCI, NII, DN |
| CBD |
Low-moderate |
Variable |
Usually minimal |
- Prevalence: 5-10% of CBS cases
- Mechanism: Progranulin haploinsufficiency
- Inheritance: Autosomal dominant
- Onset: Earlier (55-65 years)
- Prevalence: 2-5% of CBS cases
- Mechanism: Hexanucleotide repeat expansion
- DPR toxicity: Bidirectional translation products
- Phenotype: Often with ALS/FTD features
- Risk allele: rs1991730 (G allele)
- Effect: Modulates TDP-43 pathology
- Population frequency: ~40%
- VCP mutations: Rare but described
- CHCHD10: Associated with FTD-ALS spectrum
- SQSTM1: Autophagy/ubiquitin pathway
| Feature |
TDP-43 CBS |
Tau-predominant CBS |
| Motor onset |
More common |
Variable |
| Cortical signs |
Prominent |
Prominent |
| ALS features |
15-20% |
Rare |
| Cognitive profile |
Language-predominant |
Executive-predominant |
| Progression |
Variable |
Typically slower |
TDP-43 pathology correlates with specific clinical features:
-
Speech/Language Onset
- Higher likelihood of language-predominant presentation
- May present as progressive aphasia first
-
Motor Neuron Disease Overlap
- Presence of upper motor neuron signs
- Bulbar dysfunction
- Fasciculations
-
Cognitive Profile
- More prominent language impairment
- Less prominent executive dysfunction initially
- Disease duration: Variable; no consistent difference from tau-predominant
- Progression rate: Individual variation; not predictably different
- Treatment response: May influence response to future targeted therapies
| Marker |
TDP-43 CBS |
Tau-predominant CBS |
| NfL |
Elevated |
Elevated |
| p-tau181 |
Normal-low |
Elevated |
| TDP-43 |
Elevated |
Normal |
| β-amyloid |
Variable |
Often positive |
- MRI: Frontoparietal atrophy, similar to tau-predominant
- FDG-PET: Hypometabolism in affected regions
- PET tau ligands: Usually negative or low signal (distinguishes from AD)
No TDP-43-specific therapies exist. Current approach:
- Symptomatic treatment of motor and cognitive features
- Multidisciplinary care
- Physical, occupational, speech therapy
- GRN replacement: AAV-delivered progranulin
- Antisense oligonucleotides: Targeting GRN mRNA
- Autophagy enhancers: Promoting TDP-43 clearance
- Protein aggregation inhibitors: Preventing inclusion formation
- Anti-TDP-43 antibodies: Active or passive immunization
- Currently in preclinical development
TDP-43 pathology has implications for trial design:
- Stratification: Biomarker-based patient selection
- Endpoint selection: Disease-specific measures
- Outcome biomarkers: CSF TDP-43, neuroimaging
Priority areas:
- Blood-based biomarkers: Phosphorylated TDP-43
- PET ligands: Specific for TDP-43 inclusions
- Extracellular TDP-43: Detectable in CSF or blood
¶ Understanding Pathogenesis
Key questions:
- Mechanisms of mislocalization: Nuclear export abnormalities
- Aggregation processes: Post-translational modifications
- Cell-to-cell spread: Prion-like propagation
Active research areas:
- Nuclear import/export: Restoring proper localization
- Protein clearance: Autophagy, proteasome enhancement
- Gene regulation: Epigenetic approaches
- Mackenzie et al., TDP-43 pathology in CBS (2011)
- Rohrer et al., TDP-43 clinical phenotypes (2012)
- Ghoshal et al., TDP-43 and CBD (2012)
- Boeve et al., C9orf72 in CBS (2012)
- Gao et al., GRN mutations in CBS (2011)
- Palleis et al., Biomarker classification of CBS (2024)
- Chahine et al., TDP-43 in neurodegenerative disease (2014)
- Nicoletti et al., TDP-43 biomarkers in CSF (2023)
- Deleon et al., TDP-43 PET imaging (2024)
- Smith et al., Progranulin therapy for CBS (2023)